1ST INTERNATIONAL CONGRESS OF MICRO-IMMUNOTHERAPY
University of the Balearic Islands #Mallorca, SPAIN
It is a great pleasure for me to invite you to the 1st International Congress of Micro-Immunotherapy (ICoMI), which will be held between 18-20 May, 2017 in the beautiful city of Palma de Mallorca. The main topic of the congress is: “Immunomodulation and chronic diseases through the prism of autoimmunity: new concepts, new perspectives”.
Why is it important to address this topic? According to the American Autoimmune Related Diseases Association (AARDA), more than 50 million Americans suffer from different types of autoimmune disorders, and the prevalence is rising. Autoimmune diseases are one of the top 10 leading causes of death in women aged more than 64 . On the other hand, chronic diseases and conditions – such as cardio-vascular diseases, cancer, metabolic syndrome, diabetes, obesity, etc. – continue to increase dramatically, and represent a major health and economic burden. A better understanding of the risk factors, of the common pathogenic mechanisms and the natural history of these diseases will help establish preventive care practices, and improve the actual therapeutic strategies.
In this regard, it has become more and more evident that inflammatory processes and immune dysfunction promote the development and progression of numerous chronic pathologies. This has lead to a more precise understanding of the pathophysiology of these disorders (including the role of barrier function) and to the establishment of a new concept of autoimmunity.
Therefore, it is essential to restore the balance of the immune system in order to obtain sustainable results. Immunomodulation, by means of Immunotherapy or other therapeutic approaches based on low doses like Micro-Immunotherapy, can make an important contribution to the treatment of those diseases.
Several of those aspects will be presented and discussed during the congress in 2017. I look forward to welcoming you there and interchanging ideas in the above-mentioned field for the benefit of patients.
Pr. Tomohiro KUROSAKI (Osaka, Japan)
– Professor in Laboratory of Lymphocyte Differentiation at WPI Immunology Frontier Research Center, Osaka University
– Group Director in Laboratory for Lymphocyte Differentiation at RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan
After receiving his PhD from Kyoto University in 1987, Tomohiro Kurosaki took several positions; including as Research Associate at Sloan-Kettering Institute, Senior Research Scientist at Lederle Laboratories, and Professor at Kansai Medical University. Since 2004, he has served as Group Director of Laboratory for Lymphocyte Differentiation at RIKEN Research Center for Allergy and Immunology (renamed as RIKEN Center for Integrative Medical Sciences in 2013). In 2008, he joined the WPI Immunology Frontier Research Center, Osaka University, as Principal Investigator and has led Laboratory of Lymphocyte Differentiation ever since. His main research interest is activation mechanism of B lymphocytes.
Jordi LalucatPr. Jorge LALUCAT JO (Palma de Mallorca, Spain)
Microbiology Professor in the Biology Department at the Balearic Islands University
Jorge Lalucat Jo did his Predoctoral Scholarship in the Institute of Microbiology at the University of Göttingen (Germany) and obtained his PhD in Microbiology from the University of Barcelona in 1977. He entered the Balearic Island University in 1982 as Director of the Microbiology Department and has been consecutively Director of the Institute of Advanced Studies of the Balearic Islands University as well as Deputy Director of the Department of Environmental Biology, President of the Specialized Group for Taxonomy, Phylogeny and Biodiversity of the Spanish Society for Microbiology and Vice-Rector of Research at the Balearic Islands University. His studies have been punctuated by various stays in foreign centres (Universities of South Dakota, Stanford and Berkeley, USA, University of Norwich, United Kingdom and Malmö General Hospital Sweden).
Mark LarchéPr. Mark LARCHÉ (Ontario, Canada)
– Professor in the Department of Medicine at McMaster University, Hamilton Ontario, Canada
– Canada Research Chair in Allergy & Immune Tolerance & McMaster University/GSK Chair in Lung Immunology at St. Joseph’s Healthcare, Hamilton
Mark Larché received his PhD in Immunology from the University of London in 1990. He completed postdoctoral training at St. Jude Children’s Research Hospital, Memphis Tennessee and St. Mary’s Hospital Medical School, London, prior to joining the Faculty at Imperial College London in 1995. In 2006 he was appointed Canada Research Chair in Allergy & Immune Tolerance at McMaster University. His research interests include the pathogenesis and treatment of chronic inflammation with a particular focus on allergic diseases, immunological mechanisms of immunotherapy, pathogenesis of autoimmune diseases (rheumatoid arthritis and scleroderma) and graft rejection. Over the past 20 years he has developed peptide immunotherapies based on the delivery of immunodominant T cell epitopes to induce immune tolerance. Dr. Larché is a co-founder of Circassia Ltd., a biotechnology company developing vaccines for allergic diseases. More recently he was Founding Scientist of Adiga Life Sciences, a Joint Venture between Circassia Ltd and McMaster University.
Group registrations not allowed
Accompanying persons not allowed
We don’t accept Online Abstracts
University of the Balearic Islands
Carretera de Valldemossa, km 7.5
Palma de Mallorca
Polly Gartrell , Congress Coordinator , DIMI S.L.
Polly Gartrell , Congress Coordinator , DIMI S.L.